Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor Receptor 2 (HER2)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07788196
What this trial is testing

A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.

Who this might be right for
IB-II Gastric Cancer
Xijing Hospital 120
Large-scale testing (Phase 3)Not Yet RecruitingNCT06944496
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Carcinoma
RemeGen Co., Ltd. 616
Testing effectiveness (Phase 2)Active Not RecruitingNCT07176702
What this trial is testing

A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy

Who this might be right for
Metastatic PDACHER2-positive Status
Shanghai Zhongshan Hospital 45
Testing effectiveness (Phase 2)Ended earlyNCT02000596
What this trial is testing

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Who this might be right for
Metastatic Breast Cancer
University of Maryland, Baltimore 2
Testing effectiveness (Phase 2)UnknownNCT05154396
What this trial is testing

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Chinese Academy of Medical Sciences 60
Not applicableUnknownNCT04683770
What this trial is testing

Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200
Early research (Phase 1)Looking for participantsNCT07369505
What this trial is testing

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Who this might be right for
Breast Cancer MetastaticRenal Cell Carcinoma (RCC)Neuroendocrine Tumors+2 more
SAPU NANO (US) LLC 27
Testing effectiveness (Phase 2)Study completedNCT00436566
What this trial is testing

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Who this might be right for
Breast CancerCardiac Toxicity
Mayo Clinic 122
Early research (Phase 1)Study completedNCT00462956
What this trial is testing

GW572016 In Patients With Advanced Or Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 59
Very early researchEnrolling By InvitationNCT07023861
What this trial is testing

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

Who this might be right for
Breast CancerGastric Cancer (GC)Urothelial Carcinoma (UC)
Affiliated Hospital of Jiangnan University 20
Not applicableUnknownNCT06156761
What this trial is testing

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 24
Testing effectiveness (Phase 2)WithdrawnNCT05678205
What this trial is testing

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma
Artiva Biotherapeutics, Inc.
Early research (Phase 1)Looking for participantsNCT04686305
What this trial is testing

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 304
Testing effectiveness (Phase 2)UnknownNCT05721651
What this trial is testing

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Who this might be right for
Gastric Cancer
Wu Jun 60
Not applicableAvailableNCT07643831
What this trial is testing

Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

Who this might be right for
ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
Genentech, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT06764186
What this trial is testing

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
AstraZeneca 101
Early research (Phase 1)Study completedNCT01246102
What this trial is testing

AT13387 in Adults With Refractory Solid Tumors

Who this might be right for
Solid TumorsBreast Cancer
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Looking for participantsNCT06486883
What this trial is testing

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

Who this might be right for
Advanced Breast CancerAdvanced Breast CarcinomaHormone Receptor Positive Breast Carcinoma
MedSIR 200
Very early researchStudy completedNCT01875666
What this trial is testing

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Who this might be right for
Breast Neoplasms
UNC Lineberger Comprehensive Cancer Center 26
Testing effectiveness (Phase 2)Study completedNCT01472029
What this trial is testing

Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Stomach
AIO-Studien-gGmbH 53
Next Page